Medpace (MEDP) closed the most recent trading day at $343.05, moving +1.57% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.9%. Meanwhile, the Dow gained 0.81%, and the Nasdaq, a tech-heavy index, added 1.22%. The provider of outsourced clinical development services's shares have seen a decrease of 2.78% over the last month, surpassing the Medical sector's loss of 4.05% and falling behind the S&P 500's gain of 3.15%. Market participants will be close ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MEDP. Investigation Details On September 25, 2025, Jefferies downgraded Medpace, citing perceived weaknesses in the Com ...

In the latest market close, Medpace (MEDP) reached $354.65, with a -0.57% movement compared to the previous day. This change lagged the S&P 500's 0.03% gain on the day. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.2%. The provider of outsourced clinical development services's stock has dropped by 9.01% in the past month, falling short of the Medical sector's gain of 2.67% and the S&P 500's gain of 1.54%. The upcoming earnings release of Medpace will ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about Medpace (MEDP) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Medpace currently has an average brokerage recommendation (ABR ...

Medpace (MEDP) closed the latest trading day at $339.38, indicating a +1.08% change from the previous session's end. This change lagged the S&P 500's 1.16% gain on the day. Elsewhere, the Dow gained 1.2%, while the tech-heavy Nasdaq added 1.16%. Shares of the provider of outsourced clinical development services have depreciated by 13.17% over the course of the past month, underperforming the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48%. Analysts and investors alike will be keeping a close e ...

I I F ■ F Matteo Colombo Investment update Following my January '23 publication rating Medpace Holdings (NASDAQ:MEDP) a buy, the stock is +69% and has vindicated the original buy thesis presented in July '22 (I had reinstated the buy rating several times in between these two dates as well). The January publication outlined numerous investment facts that are still explicitly relevant in the investment debate today, namely: Profitability is a standout with ROICs at +33% trailing return on invested capital dri ...

Core Viewpoint - Medpace Holdings, Inc. has faced significant stock price decline following disappointing second quarter 2024 financial results, raising concerns about potential violations of federal securities laws and unlawful business practices [2][1]. Financial Performance - On July 22, 2024, Medpace reported second quarter 2024 financial results that significantly missed market expectations [2]. - The company experienced disproportionately high cancellations in June 2024, attributed to factors such as reprioritization, impaired sponsor liquidity, and a large pharmaceutical acquisition that led to work being shifted to a preferred provider [2]. Stock Market Reaction - Following the earnings announcement, Medpace's stock price dropped by $79.88, or 18.3%, closing at $357.30 per share on July 23, 2024, resulting in losses for investors [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Medpace on behalf of its stockholders regarding possible violations of federal securities laws and other unlawful business practices [1].

SAN FRANCISCO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Medpace Holdings, Inc. (NASDAQ: MEDP) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/MEDP Contact the Firm Now: MEDP@hbsslaw.com 844-916-0895 Medpace Holdings, Inc. (MEDP) Investigation: Medpace Holdings, Inc. is facing scrutiny over its recent financial perform ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task. Medpace (MEDP) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. While the historical EPS growth rate for Medpace is 32.2%, investors should actually focus o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 _________________________ ...